ATE389415T1 - Verfahren und mittel zur erhöhung der darmabsorption - Google Patents
Verfahren und mittel zur erhöhung der darmabsorptionInfo
- Publication number
- ATE389415T1 ATE389415T1 AT03760706T AT03760706T ATE389415T1 AT E389415 T1 ATE389415 T1 AT E389415T1 AT 03760706 T AT03760706 T AT 03760706T AT 03760706 T AT03760706 T AT 03760706T AT E389415 T1 ATE389415 T1 AT E389415T1
- Authority
- AT
- Austria
- Prior art keywords
- increase intestinal
- egf
- intestinal absorption
- relates
- producing
- Prior art date
Links
- 230000031891 intestinal absorption Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 1
- 101800003838 Epidermal growth factor Proteins 0.000 abstract 1
- 244000199866 Lactobacillus casei Species 0.000 abstract 1
- 235000013958 Lactobacillus casei Nutrition 0.000 abstract 1
- 241000194035 Lactococcus lactis Species 0.000 abstract 1
- 206010049416 Short-bowel syndrome Diseases 0.000 abstract 1
- 235000014897 Streptococcus lactis Nutrition 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 229940116977 epidermal growth factor Drugs 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 235000014655 lactic acid Nutrition 0.000 abstract 1
- 239000004310 lactic acid Substances 0.000 abstract 1
- 229940017800 lactobacillus casei Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Surgery (AREA)
- Endocrinology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Radio Relay Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02077532 | 2002-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE389415T1 true ATE389415T1 (de) | 2008-04-15 |
Family
ID=29797233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03760706T ATE389415T1 (de) | 2002-06-19 | 2003-06-19 | Verfahren und mittel zur erhöhung der darmabsorption |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7601799B2 (de) |
| EP (1) | EP1513545B1 (de) |
| JP (1) | JP2005529622A (de) |
| AT (1) | ATE389415T1 (de) |
| AU (1) | AU2003250250B2 (de) |
| CA (1) | CA2489930A1 (de) |
| DE (1) | DE60319822T2 (de) |
| ES (1) | ES2302945T3 (de) |
| WO (1) | WO2004001020A2 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60319822T2 (de) | 2002-06-19 | 2009-06-04 | Actogenix Nv | Verfahren und mittel zur erhöhung der darmabsorption |
| DK2119450T3 (da) | 2005-11-29 | 2013-05-06 | Actogenix Nv | Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener |
| BRPI0807857A2 (pt) | 2007-01-25 | 2014-05-27 | Actogenix Nv | Tratamento de doença imune por meio de distribuição através da mucosa de antígenos. |
| JP2012504116A (ja) * | 2008-09-29 | 2012-02-16 | アクトジェニックス・エヌブイ | 粘膜での微生物のコロニー形成の低減 |
| KR101667982B1 (ko) * | 2010-01-14 | 2016-10-20 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 염증성 장 질환(ibd) 및 과민성 장 증후군(ibs)의 예방 및 치료를 위한 재조합 프로바이오틱 박테리아 |
| EP2830599B1 (de) | 2012-03-29 | 2018-08-15 | Therabiome, Llc | Ortsspezifische gastrointestinale orale impfrezepte zur wirkung am ileum und am blinddarm |
| US9907755B2 (en) | 2013-03-14 | 2018-03-06 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| CN103710351B (zh) * | 2013-12-23 | 2015-12-09 | 江苏众红生物工程创药研究院有限公司 | 表皮生长因子重组乳酸菌及其应用 |
| CN107325998A (zh) * | 2017-06-20 | 2017-11-07 | 江西嘉博生物工程有限公司 | 一种表达猪表皮生长因子基因的重组乳酸乳球菌及构建方法 |
| JP7316802B2 (ja) * | 2019-02-19 | 2023-07-28 | 雪印メグミルク株式会社 | 糖吸収促進用組成物 |
| IT201900014550A1 (it) * | 2019-08-09 | 2021-02-09 | Abiogen Pharma Spa | Uso di colecalciferolo come agente attivo nel trattamento della celiachia |
| CN116676246A (zh) * | 2023-06-16 | 2023-09-01 | 华中农业大学 | 重组乳酸乳球菌、益生菌制剂、构建方法、cECF表达方法及应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4100495A (en) | 1975-11-27 | 1978-07-11 | Cselt - Centro Studi E Laboratori Telecomunicazioni | Adaptive method of and means for recovering digital signals |
| US4190495A (en) | 1976-09-27 | 1980-02-26 | Research Corporation | Modified microorganisms and method of preparing and using same |
| US4874702A (en) | 1980-09-08 | 1989-10-17 | Biogen, Inc. | Vectors and methods for making such vectors and for expressive cloned genes |
| US4888170A (en) | 1981-10-22 | 1989-12-19 | Research Corporation | Vaccines obtained from antigenic gene products of recombinant genes |
| US5417986A (en) | 1984-03-16 | 1995-05-23 | The United States Of America As Represented By The Secretary Of The Army | Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres |
| DE3578852D1 (de) | 1984-09-26 | 1990-08-30 | Lilly Co Eli | Verfahren zur expression und sekretion in bacillus. |
| US5032510A (en) | 1984-09-26 | 1991-07-16 | Eli Lilly And Company | Method for expression and secretion in bacillus |
| WO1988006626A1 (en) | 1987-03-02 | 1988-09-07 | Whitehead Institute For Biomedical Research | Recombinant mycobacterial vaccine |
| US5591632A (en) | 1987-03-02 | 1997-01-07 | Beth Israel Hospital | Recombinant BCG |
| US5504005A (en) | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
| US5330753A (en) | 1987-04-29 | 1994-07-19 | President And Fellows Of Harvard College | Cholera vaccines |
| US6130082A (en) | 1988-05-05 | 2000-10-10 | American Cyanamid Company | Recombinant flagellin vaccines |
| US5972685A (en) | 1988-07-21 | 1999-10-26 | Iowa State University Research Foundation, Inc. | Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration |
| IE892131A1 (en) | 1989-06-30 | 1991-01-02 | Univ Cork | Marker genes for genetic manipulation |
| US5149532A (en) | 1989-11-01 | 1992-09-22 | Cedars Sinai Medical Center | Method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms |
| DE4006521A1 (de) | 1990-03-02 | 1991-09-05 | Bayer Ag | Zuckerhaltige polymere zur umhuellung und einbettung von arzneistoffen |
| GB9006400D0 (en) | 1990-03-22 | 1990-05-23 | Ciba Geigy Ag | Bacterial vectors |
| IL99097A0 (en) | 1990-09-05 | 1992-07-15 | Akzo Nv | Haemophilus paragallinarum vaccine |
| SK55593A3 (en) | 1991-03-05 | 1993-10-06 | Wellcome Found | Expresion of recombinant proteins in attenuated bacteria |
| EP0607278B1 (de) | 1991-10-07 | 2002-04-17 | The Brigham And Women's Hospital, Inc. | Verfahren zur erhöhung der darmabsorption |
| IL103530A0 (en) | 1991-10-25 | 1993-03-15 | Duphar Int Res | Treponema hyodysenteriae vaccine |
| EP0628083A1 (de) | 1992-02-27 | 1994-12-14 | Microbial Technics Limited | Heterologe genexpression in lactococcus und die entsprechenden expressionsprodukte |
| US5455034A (en) | 1992-06-26 | 1995-10-03 | Kansas State University Research Foundation | Fusobacterium necrophorum leukotoxoid vaccine |
| DE4231764A1 (de) | 1992-09-23 | 1994-03-24 | Inst Pflanzengenetik & Kultur | Verfahren zur chromosomalen Integration eines Produkt-Gens |
| US5691185A (en) | 1993-10-08 | 1997-11-25 | Chr. Hansen A/S | Lactic acid bacterial suppressor mutants and their use as selective markers and as means of containment in lactic acid bacteria |
| CA2173751A1 (en) | 1993-10-13 | 1995-04-20 | Sýren Molin | Recombinant staphylococcal nucleases and their use in limiting the survival of genetically engineered microorganisms |
| IT1270123B (it) * | 1994-10-05 | 1997-04-28 | Dompe Spa | Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia |
| US5733540A (en) | 1995-03-08 | 1998-03-31 | Lee; Peter Poon-Hang | Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria |
| US5753622A (en) | 1995-05-10 | 1998-05-19 | University Technologies International, Inc. | Use of epidermal growth factor as a gastrointestinal therapeutic agent |
| ATE312934T1 (de) | 1995-06-07 | 2005-12-15 | Univ Washington | Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit |
| US5824538A (en) | 1995-09-06 | 1998-10-20 | The United States Of America As Represented By The Secretary Of The Army | Shigella vector for delivering DNA to a mammalian cell |
| GB9518323D0 (en) | 1995-09-07 | 1995-11-08 | Steidler Lothar | Materials and methods relating to the attachment and display of substances on cell surfaces |
| GB9521568D0 (en) | 1995-10-20 | 1995-12-20 | Lynxvale Ltd | Delivery of biologically active polypeptides |
| JP2000510332A (ja) | 1996-04-19 | 2000-08-15 | ヘンリー エム.ジャクソン ファンデーション フォー ザ アドバンスメント オブ ミリタリー メディシン | インチミンを単独で、または1以上の他の抗原との融合タンパク質として発現する宿主生物の投与による、免疫応答を刺激する方法 |
| US5972887A (en) | 1996-09-19 | 1999-10-26 | The Nemours Foundation | Treatment of intestinal epithelial cell malfunctions with Hepatocyte Growth Factor |
| GB9700939D0 (en) | 1997-01-17 | 1997-03-05 | Microbial Technics Limited | Therapy |
| DE69942249D1 (de) | 1998-05-07 | 2010-05-27 | Univ Bruxelles | Auf cytotoxinen basierendes biologisches einschlusssystem |
| US6190669B1 (en) | 1998-05-13 | 2001-02-20 | University Of Maryland, Baltimore | Attenuated mutants of salmonella which constitutively express the Vi antigen |
| WO2000001799A2 (en) | 1998-07-03 | 2000-01-13 | Chr. Hansen A/S | Method of preventing bacteriophage infection of bacterial cultures |
| WO2000018377A1 (en) | 1998-09-28 | 2000-04-06 | Warner-Lambert Company | Enteric and colonic delivery using hpmc capsules |
| WO2000022909A2 (en) | 1998-10-19 | 2000-04-27 | Biotech Australia Pty. Limited | Systems for oral delivery |
| EP1123314B1 (de) * | 1998-10-20 | 2004-02-18 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis |
| CA2446776C (en) | 2001-05-03 | 2011-07-12 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Self-containing lactococcus strain |
| EP1319410A1 (de) * | 2001-12-11 | 2003-06-18 | Société des Produits Nestlé S.A. | Verwendung von Mikroorganismen zur gezielten Verabreichung von Mitteln in specifischen Teilen des Darms |
| US20040043003A1 (en) | 2002-01-31 | 2004-03-04 | Wei Chen | Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions |
| DE60319822T2 (de) | 2002-06-19 | 2009-06-04 | Actogenix Nv | Verfahren und mittel zur erhöhung der darmabsorption |
| AU2003298291A1 (en) | 2002-11-15 | 2004-06-15 | Universiteit Gent | Self-containing lactobacillus strain |
-
2003
- 2003-06-19 DE DE60319822T patent/DE60319822T2/de not_active Expired - Lifetime
- 2003-06-19 ES ES03760706T patent/ES2302945T3/es not_active Expired - Lifetime
- 2003-06-19 WO PCT/EP2003/050242 patent/WO2004001020A2/en not_active Ceased
- 2003-06-19 AU AU2003250250A patent/AU2003250250B2/en not_active Ceased
- 2003-06-19 AT AT03760706T patent/ATE389415T1/de not_active IP Right Cessation
- 2003-06-19 CA CA002489930A patent/CA2489930A1/en not_active Abandoned
- 2003-06-19 JP JP2004514876A patent/JP2005529622A/ja active Pending
- 2003-06-19 EP EP03760706A patent/EP1513545B1/de not_active Expired - Lifetime
-
2004
- 2004-12-20 US US11/018,188 patent/US7601799B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003250250B2 (en) | 2008-02-14 |
| EP1513545A2 (de) | 2005-03-16 |
| US7601799B2 (en) | 2009-10-13 |
| AU2003250250A1 (en) | 2004-01-06 |
| WO2004001020A2 (en) | 2003-12-31 |
| DE60319822T2 (de) | 2009-06-04 |
| JP2005529622A (ja) | 2005-10-06 |
| WO2004001020A3 (en) | 2004-03-04 |
| CA2489930A1 (en) | 2003-12-31 |
| ES2302945T3 (es) | 2008-08-01 |
| US20050158282A1 (en) | 2005-07-21 |
| EP1513545B1 (de) | 2008-03-19 |
| DE60319822D1 (de) | 2008-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60319822D1 (de) | Verfahren und mittel zur erhöhung der darmabsorption | |
| ATE421256T1 (de) | Probiotische zusammensetzung | |
| ATE489853T1 (de) | Verbesserung des wachstums von bifidobakterien in fermentierten milchprodukten | |
| WO2009043856A3 (en) | Modulation of tissue fatty acid composition of a host by human gut bacteria | |
| EP1567660A4 (de) | MIT MILCHSûUREBAKTERIEN VERGORENERGINSENG, DIESEN ENTHALTENDER JOGHURT SOWIE ZUR HERSTELLUNG DAVON VERWENDETEMILCHSûUREBAKTERIEN | |
| DE602004006133D1 (de) | Neue galactooligosaccharidzusammensetzung und herstellung davon | |
| ATE439138T1 (de) | Probiotika zur primären prävention atopischer erkrankungen | |
| ATE444074T1 (de) | Antiallergisches mittel, seine verwendung zur verringerung von allergien und verfahren zur verringerung von allergien | |
| EP1510570A3 (de) | Verfahren zur Herstellung der L-Histidine durch die Verwendung von Bakterien aus der Familie Enterobacteriaceae | |
| ATE454443T1 (de) | Verfahren zur herstellung anallergischer probiotischer bakterienkulturen und entsprechende verwendung | |
| DE60123986D1 (de) | Verwendung eines mittels zur verbesserung des knochenmetabolismus | |
| WO2008078387A1 (ja) | 皮膚改善用及び/又は治療用の発酵乳とその製造方法 | |
| ATE480248T1 (de) | Verwendung von milchsäurebakterien zur verringerung von zahnfleischbluten und mundentzündung | |
| WO2003045405A3 (fr) | Bacteries lactiques et leur usage dans le traitement et la prevention du cancer | |
| ATE306821T1 (de) | Pulver zum ansatz für eine probiotische joghurtspeise | |
| MXPA04005346A (es) | Uso de microorganismos para una distribucion dirigida de sustancias a partes especificas del intestino. | |
| ATE451018T1 (de) | Verfahren zur herstellung von sauermilchprodukten mit enzymen bakteriellen ursprungs | |
| EP3752627A4 (de) | Mikroorganismen und verfahren zur herstellung von milchsäure | |
| DE602004023098D1 (de) | Neues lactobacillus, den lebenden körper aktivierende lactobacilluspräparation sowie präventivmittel oder therapeutikum gegen eine infektion des lebenden körpers | |
| ATE541468T1 (de) | Mikrobielle futterergänzungsmittel und verwendungen davon in verfahren zur verringerung und/oder verhinderung von azidose in polygastrischen pflanzenfressern | |
| WO2007015132A3 (en) | Use of specific lactic bacteria for the preparation of immunomodulating compositions | |
| BR0308227A (pt) | Método para melhorar os procedimentos de fermentação de alimentos | |
| ATE542887T1 (de) | Neuartiger milchsäurebakterienstrang, fermentiertes nahrungsmittel/getränk und verfahren zur herstellung eines fermentierten nahrungsmittels/getränks | |
| RU2010153265A (ru) | Способ уменьшения урчания в животе путем введения бактерий рода bifidobacterium | |
| DE50107566D1 (de) | Nukleotidsequenzen kodierend fur proteine beteiligt an der biosynthese von l-serin, verbessertes verfahren zur mikrobiellen herstellung von l-serin sowie ein dazu geeigneter genetisch veranderter mikroorganismus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |